Nationwide Statistical Analysis of Lymphoid Malignancies in Korea

被引:50
|
作者
Lee, Hyewon [1 ]
Park, Hyeon Jin [2 ]
Park, Eun-Hye [3 ]
Ju, Hee Young [2 ]
Oh, Chang-Mo [3 ]
Kong, Hyun-Joo [3 ]
Jung, Kyu-Won [3 ]
Park, Byung-Kiu [2 ]
Lee, Eunyoung [1 ]
Eom, Hyeon-Seok [1 ,4 ]
Won, Young-Joo [3 ,5 ]
机构
[1] Res Inst & Hosp, Natl Canc Ctr, Ctr Hematol Malignancy, 323 Ilsan Ro, Goyang 10408, South Korea
[2] Res Inst & Hosp, Natl Canc Ctr, Ctr Pediat Oncol, Goyang, South Korea
[3] Natl Canc Ctr, Canc Registrat & Stat Branch, 323 Ilsan Ro, Goyang 10408, South Korea
[4] Natl Canc Ctr, Grad Sch Canc Sci & Policy, Dept Syst Canc Sci, Goyang, South Korea
[5] Natl Canc Ctr, Grad Sch Canc Sci & Policy, Dept Canc Control & Policy, Goyang, South Korea
来源
CANCER RESEARCH AND TREATMENT | 2018年 / 50卷 / 01期
关键词
Epidemiology; Incidence; Survival; Hematologic neoplasms; Republic of Korea; HODGKINS-LYMPHOMA; CELL LYMPHOMA; CANCER STATISTICS; CLASSIFICATION; PROPOSALS; NEOPLASMS; SURVIVAL; ADULTS; TRENDS;
D O I
10.4143/crt.2017.093
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Regional differences in the incidence of lymphoid malignancies have been reported worldwide, but there has been no large-scale epidemiologic analysis in Korea. The aim of this study was to provide a nationwide population-based statistical analysis of Korean patients with lymphoid malignancies. Materials and Methods The Korea Central Cancer Registry analyzed the incidence and survival of patients with lymphoid malignancies from the Korean National Cancer Incidence Database. Diseases were grouped by clinically relevant categories based on the 2008 World Health Organization classification. Results Overall 65,948 lymphoid diseases were identified between 1999 and 2012. The incidence of most subtypes increased with age, except for precursor cell neoplasms. Male predominance (male: female ratio=1.28:1) was observed. In 2012, annual age-standardized incidence rates per 100,000 persons of Hodgkin's lymphoma, mature B-cell neoplasm, mature T/natural killer (NK)-cell neoplasm, and precursor cell neoplasm were 0.46, 6.60, 0.95, and 1.50, respectively, and they increased yearly from 1999. Composite Hodgkin's and non-Hodgkin's lymphomas were extremely rare. Survival improvement estimated using 5-year relative survival rate was observed in patients with Hodgkin's lymphoma (71.1%83.0%), diffuse large B-cell lymphoma (49.5%-61.5%), plasma cell neoplasms (20.2%36.9%), and lymphoblastic lymphoma/leukemia (41.5%-56.3%) between 1993 and 2012. However, survival rates of T/NK-cell lymphoma (excluding cutaneous T-cell lymphoma) ranged from 40.5%-43.5% during the study period. Survival rates decreased with age in most subtypes. Conclusion This report presented the subtype-specific statistical analysis of lymphoid malignancies in the Korean population, showing increasing incidences and survival rates in most subtypes.
引用
收藏
页码:222 / 238
页数:17
相关论文
共 50 条
  • [21] CHARACTERISTICS OF ASTHMA PATIENTS IN KOREA BY THE ANALYSIS OF NATIONWIDE DATABASE
    Rhee, C. K.
    Yoon, H. K.
    Yoo, K. H.
    RESPIROLOGY, 2016, 21 : 164 - 164
  • [22] Selenium and lymphoid malignancies - Reply
    Avanzini, P
    Vinceti, M
    Ilariucci, F
    HAEMATOLOGICA, 1997, 82 (01) : 123 - 124
  • [23] Novel immunotherapies in lymphoid malignancies
    Connie Lee Batlevi
    Eri Matsuki
    Renier J. Brentjens
    Anas Younes
    Nature Reviews Clinical Oncology, 2016, 13 : 25 - 40
  • [24] INTERRELATION OF B LYMPHOID MALIGNANCIES
    THIELEMANS, K
    ACTA CLINICA BELGICA, 1987, 42 (06): : 407 - 413
  • [25] DEOXYCOFORMYCIN IN LYMPHOID MALIGNANCIES - AN OVERVIEW
    ODWYER, PJ
    EISENHAUER, EA
    HOTH, DF
    INVESTIGATIONAL NEW DRUGS, 1987, 5 (01) : 68 - 68
  • [26] ADVANCES IN THE TREATMENT OF LYMPHOID MALIGNANCIES
    BERTINO, JR
    SEMINARS IN ONCOLOGY, 1986, 13 (04) : 1 - 2
  • [27] Panobinostat in lymphoid and myeloid malignancies
    Khot, Amit
    Dickinson, Michael
    Prince, H. Miles
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (09) : 1211 - 1223
  • [28] Novel immunotherapies in lymphoid malignancies
    Batlevi, Connie Lee
    Matsuki, Eri
    Brentjens, Renier J.
    Younes, Anas
    NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (01) : 25 - 40
  • [29] Ibrutinib in B lymphoid malignancies
    Smith, Mitchell R.
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (12) : 1879 - 1887
  • [30] ATM gene and lymphoid malignancies
    F Gumy-Pause
    P Wacker
    A-P Sappino
    Leukemia, 2004, 18 : 238 - 242